Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites

Objective: The aim of this study was to explore the effects of neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and ascites. Materials and Methods: One hundred eight senile patients with advanced ovarian cancer and ascites were randomly divided into two groups: experimental and control groups. Patients in the experimental group were treated with two courses of intraperitoneal combined with intravenous neoadjuvant chemotherapy, followed by cytoreductive surgery, and six courses of intravenous chemotherapy, while the patients in the control group only received cytoreductive surgery and six to eight courses of intravenous chemotherapy. Results: The operation duration, blood loss, ideal success rate of cytoreductive surgery, and prognosis of the two groups were then compared. Thirty-eight patients in the experimental group successfully received cytoreductive surgery, accounting for 74.14%, while only 23 patients in the control group received cytoreductive surgery successfully, accounting for 46%, showing significant difference between the two groups (p = 0.0054). The mean blood loss and operation duration in the experimental group were significantly less than those in the control group (p < 0.001). However, the median survival and the median progression-free survival showed no statistical difference between the two groups (p > 0.05). Conclusions: Neoadjuvant chemotherapy can obviously shorten the operation duration, reduce the intraoperative blood loss, and improve the ideal success rate of cytoreductive surgery, but does not obviously improve the prognosis.

Abdominal combined with venous neoadjuvant chemotherapy; Senile patients; Advanced ovarian cancer; Ascites.

[1] National Center for Health Statistics.: “With special feature on socioeconomic status and health”. Hyattsville (MD). Health, United States, 2012, 2011, 1232.

[2] Tew W.P., Lichtman S.: “Ovarian cancer in older women”. Semin. Oncol., 2008, 35, 582.

[3] Tew W.P., Java J., Chi D., Menzin A., Lovecchio J.L., Bookman M.A., et al.: “Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182)”. J. Clin. Oncol., 2010, 28, 5030.

[4] Maas H.A., Kruitwagen R.F., Lemmens V.E., Goey S.H., Janssen- Heijnen M.L.: “The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study”. Gynecol. Oncol., 2005, 97, 104.

[5] Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., et al.: “Ageasaprognostic factoring ovariancarcinoma. The Gynecologic Oncology Group experience”. Cancer, 1993, 71, 606.

[6] Hightower R.D., Nguyen H.N., Averette H.E., Hoskins W., Harrison T., Steren A.: “National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients”. Cancer, 1994, 73, 377.

[7] Milam M.R., Tao X., Coleman R.L., Harrell R., Bassett R., Dos Reis R., et al.: “Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2011, 21, 66.

[8] Rowland M.R., Lesnock J.L., Farris C., Kelley J.L., Krivak T.C: “Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older”. Am. J. Obstet. Gynecol., 2015, 212, 763.e1.

[9] Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., et al.: “Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial”. J. Clin. Oncol., 2013, 31, abstr 5500.

[10] Poonawalla I.B., Lairson D.R., Chan W., Piller L.B., Du X.L.: “Costeffectiveness of neoadjuvant chemotherapy versus primary surgery in elderly patients with advanced ovarian cancer”. Value Health, 2015, 18, 387.

[11] Seigal R., Naishadham D., Jemal A.: “Cancer statistics”. CA. Cancer. J. Clin., 2012, 62, 10.

[12] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics”. CA Cancer. J. Clin., 2002, 2005, 74.

[13] Lopes J.A., Krikorian J.G., Reich S.D., Smyth R.D., Lee F.H., Issell B.F.: “Clinical pharmacology of intraperitoneal cisplatin”. Gynecol. Oncol., 1985, 20, 1.

[14] Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis J.L. Jr., et al.: “Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1992, 10, 1485.

[15] Markman M.: “Unresolve disease in the themotherapautic management of gynecologic malignanies”. Semin. Oncol., 2006, 33, S33.

[16] Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., et al.: “Intraperitoneal themtherapy in the first-line treatment of women with stage III epithealial ovarian cancer: a systemic review within metanalyses”. Cancer, 2007, 109, 692.

[17] Barrios M., Diaz J., Schroeder E., Estape R., Angel K., Estape R.: “Combination intraperitoneal carboplatin and intravenous and intraperitoneal Paclitaxel in the management of advanced-stage ovariancancer”. Obstet. Gynecol., 2014, 123, 90S.

[18] Vergote I., Triope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al.: “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer”. N. Engl. J. Med., 2010, 363, 943.

[19] Zeimet A.G., Reimer D., Radl A.C., Reinthaller A., Schauer C., Petru E., et al.: “Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cance”. Anticancer. Res., 2009, 29, 2803.

[20] Berry E., Matthews K.S., Singh D.K., Buttin B.M., Lurain J.R., Alvarez R.D., et al.: “An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer”. Gynaecol. Oncol., 2009, 113, 63.

[21] Cascales Campos P., Gil J., Parrilla P.: “Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients withprimary and recurrent advanced ovarian cancer”. Eur. J. Surg. Oncol., 2014, 40, 970.

[22] Fujiwara K., Nagao S., Aotani E., Hasegawa K.: “Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer”. Expert. Opin. Pharmacother., 2013, 14, 1797.